Whitepaper: iPSC manufacturing for drug discovery

Controlled manufacturing of hiPSC-derived cardiomyocytes in stirred-tank bioreactors enabling high-throughput phenotypic screening.

The lack of physiologically-relevant cell-based assays is an obstacle in drug development. Introducing human disease biology early in drug development could make it more effective. However, human primary tissues are rarely available in quantities sufficient for HTS. Although hiPSCs are suitable for disease modeling, the challenge of industrial scale manufacturing from different hiPSC sources has long remained. Here we describe how we enabled the production of batches of billions of cells.